Abstract
Thirty patients undergoing allogeneic BMT were screened post-transplant together with their marrow donors for CMV-specific T cell proliferation and the occurrence of CMV disease. Twenty-one of these patients received a marrow transplant from an HLA-matched sibling donor, and nine from an HLA-matched unrelated donor. All these patients were either CMV seropositive and/or had received a transplant from a CMV-seropositive donor. Patients were monitored for CMV-viraemia until day +100 post-BMT by PCR and virus culture, and thereafter by virus culture only when clinically indicated. The proliferative T cell response was investigated at regular monthly intervals beginning on day +30. A proliferative response to HCMV (median, day +123) was documented in these patients between day +37 and +730 post-BMT. None of the patients with a documented CMV-specific T cell proliferation on day 120 (n = 17) developed CMV disease in the later post-transplant period, but of the patients lacking CMV- specific proliferation (n = 13), 30.8% developed CMV disease after day 120. Thus, patients lacking a CMV- specific T-helper cell response might benefit from sensitive screening for CMV infection and pre-emptive therapy after day +100.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krause, H., Hebart, H., Jahn, G. et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 19, 1111–1116 (1997). https://doi.org/10.1038/sj.bmt.1700801
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700801
Keywords
This article is cited by
-
Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation
Journal of Hematology & Oncology (2017)
-
The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients
Cellular and Molecular Life Sciences (2015)
-
References
Bone Marrow Transplantation (2009)